Thermo Fisher vs. Intuitive Surgical: Which Premium Healthcare Stock Deserves its Valuation?

Premium healthcare stocks typically command higher valuations for various reasons. Regarding Thermo Fisher (NYSE:TMO), its investment case hinges on whether the life sciences sector rebounds from its post-pandemic slowdown, while Intuitive Surgical (NASDAQ:ISRG) maintains a dominant position in robotic surgery due to its highly recurring revenue model.

While both firms reported positive results, investors are scrutinizing different aspects of each company. The main question for investors is which premium valuation is better backed by long-term fundamentals.

Thermo Fisher's (NYSE:TMO) prospects rely on the recovery of life sciences spending. The company's Q2 results indicate that the revival in life sciences spending is becoming more widespread. Management reported improving customer activity across pharmaceutical and biotechnology markets, and several segments returned to robust growth.

This broad recovery is crucial because earlier signs of improvement were primarily in bioprocessing. Strong demand across multiple businesses suggests the recovery is becoming more sustainable.

Thermo Fisher's (NYSE:TMO) Life Sciences Solutions segment supported this narrative, with revenue growing 13% year-over-year and organic revenue rising 3%. This increase was driven by continued strength in the high-margin bioproduction business. The company's recovery in Analytical Instruments, which had faced weak demand for nearly two years due to slowing biotechnology funding, also signals that laboratory spending may be normalizing.

In contrast, Intuitive Surgical (NASDAQ:ISRG) justifies its premium valuation through various factors, such as its strong business model. The company's profitability margins are impressive, with a non-GAAP gross profit margin of 70.0% and a non-GAAP operating margin expanding by 330 basis points year-over-year to 42.1%. Moreover, 85% of the company's revenue comes from recurring sources, providing investors with significant visibility into future earnings as the installed base of its da Vinci surgical platform continues to grow.

The company reported a 18% year-over-year increase in da Vinci system placements, a testament to ongoing hospital investment despite broader economic uncertainties.

However, Intuitive Surgical's premium valuation comes with some risks. The company's growth guidance remained unchanged, with an expected 13.5% to 15.5% year-over-year increase in da Vinci procedure growth by 2026. This expectation may be challenging to meet, given the sensitivity of investors to any signs of slowing growth. For a company trading at a premium valuation, meeting expectations is often insufficient, as investors anticipate continued acceleration.

When comparing the two companies, Intuitive Surgical (NASDAQ:ISRG) has a higher forward P/E ratio of 37.17, which is 90.62% above the sector average, while Thermo Fisher (NYSE:TMO) trades at a forward P/E of 24.09, or 23.51% above the sector. This valuation gap indicates that investors place a significantly higher premium on Intuitive Surgical's long-term growth prospects and recurring revenue model compared to Thermo Fisher.

Institutional investors also display a slightly different sentiment, with Intuitive Surgical's hedge fund ownership decreasing from 109 funds in Q4 2025 to 103 funds in Q1 2026, while Thermo Fisher saw a modest increase in hedge fund ownership from 113 to 115 funds over the same period.